statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CytomX Therapeutics, Inc. (NASDAQ:CTMX  Free Report)  Research analysts at HC Wainwright issued their FY2025 EPS estimates for CytomX Therapeutics in a report released on Monday...

HC Wainwright Comments on CytomX Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:CTMX)

SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the...

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

CytomX Therapeutics announces milestone achievement in PROBODY TCB

- Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX - - Program is one of several ongoing collaboration...

CytomX Therapeutics Announces Milestone Achievement in PROBODY T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

CytomX Therapeutics price target lowered by 5c at BMO Capital, here's why

Q4 2023 CytomX Therapeutics Inc Earnings Call Transcript

Key Financial Highlights and Upcoming Clinical MilestonesRelated Stocks: CTMX...

CytomX Therapeutics Inc (CTMX) Reports 2023 Financial Results and Provides Pipeline Update

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 (EpCAM ADC) Phase 1 clinical study initiation in solid...

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

CytomX Therapeutics's Earnings Outlook

CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders have had their patience rewarded with a 85% share price jump in...

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Volume	167,879.00
52-Wk High	$2.86
52-Wk Low	$1.04

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.08	--	--	N/A
Q4'23	-$0.05	$0.02	141.42%	BEAT
Q3'23	-$0.19	$0.04	121.21%	BEAT
Q2'23	-$0.19	-$0.02	89.42%	BEAT
Q1'23	-$0.11	-$0.05	54.88%	BEAT

CTMX CytomX Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals